BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
11/26/2024 7:20:29 AM | Browse: 162 | Download: 779
 |
Received |
|
2024-08-20 00:26 |
|
Peer-Review Started |
|
2024-07-09 02:41 |
|
First Decision by Editorial Office Director |
|
2024-09-27 19:32 |
|
Return for Revision |
|
2024-09-27 19:32 |
|
Revised |
|
2024-10-06 00:31 |
|
Publication Fee Transferred |
|
2024-11-05 23:20 |
|
Second Decision by Editor |
|
2024-11-05 02:40 |
 |
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2024-11-05 07:19 |
|
Articles in Press |
|
2024-11-05 07:19 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2024-11-15 07:11 |
|
Publish the Manuscript Online |
|
2024-11-26 07:20 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Basic Study |
| Article Title |
Carnitine palmitoyltransferase-II inactivity promotes malignant progression of metabolic dysfunction-associated fatty liver disease via liver cancer stem cell activation
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Ling-Ling Wang, Yu-Ming Lu, Yi-Han Wang, Yi-Fan Wang, Rong-Fei Fang, Wen-Li Sai, Deng-Fu Yao and Min Yao |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| National Natural Science Foundation of China |
81873915 and 81673241 |
|
| Corresponding Author |
Min Yao, MD, PhD, Professor, Department of Immunology, Medical School, Nantong University, No. 19 Qixiu Road, Nantong 226001, Jiangsu Province, China. erbei@ntu.edu.cn |
| Key Words |
Metabolic dysfunction-associated fatty liver disease; Carnitine palmitoyl transferase-II; Mitochondria; T lymphocytes; Liver cancer stem cells |
| Core Tip |
Metabolic dysfunction-associated fatty liver disease (MAFLD) is one of the main chronic liver diseases. The present study investigated the dynamic alterations in mitochondrial carnitine palmitoyl transferase-II (CPT-II) in T cells and liver cancer stem cell (LCSC) activation in MAFLD during hepatocyte malignant progression under lipid accumulation. There was a loss of mitochondrial CPT-II activity and a decrease in the MMP with decreasing numbers of CD3+ or CD4+ T cells. Mechanistically, CPT-II inactivity via the loss of innate immune function with abnormal activation of LCSCs promotes the malignant progression of MAFLD. These results suggest that CPT-II prevents lipid accumulation and LCSC activation, as well as improves IL-CD3/CD4 T cell function for hepatocellular carcinoma immunotherapy and delays MAFLD malignant progression. |
| Publish Date |
2024-11-26 07:20 |
| Citation |
Wang LL, Lu YM, Wang YH, Wang YF, Fang RF, Sai WL, Yao DF, Yao M. Carnitine palmitoyltransferase-II inactivity promotes malignant progression of metabolic dysfunction-associated fatty liver disease via liver cancer stem cell activation. World J Gastroenterol 2024; 30(47): 5055-5069 |
| URL |
https://www.wjgnet.com/1007-9327/full/v30/i47/5055.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v30.i47.5055 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
